Sesen takes next step af­ter in­vestor at­tack, calls for share­hold­er vote to ap­prove merg­er

Two and a half weeks af­ter Sesen Bio pushed back against an in­vestor group op­pos­ing a merg­er with Caris­ma Ther­a­peu­tics, the biotech is mov­ing for­ward and call­ing a share­hold­er meet­ing for a vote.

A state­ment put out Thurs­day af­ter­noon high­light­ed how the com­pa­ny is in the mid­dle of merg­ing ef­forts with the pri­vate CAR-M play­er, as Sesen an­nounced it filed ‘de­fin­i­tive proxy ma­te­ri­als’ with the SEC as part of the process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER